- Corden Pharma announces a €900M investment to expand its Peptide technology platform over the next three years.
- The expansion includes new facilities and upgrades in the US and Europe to meet rising demand for peptide-based medications.
Corden Pharma has announced its largest strategic investment to date with a committed spend of approximately €900 million over the next three years to grow its Peptide technology platform. This ambitious expansion involves major initiatives in the US and Europe, targeting both existing facilities and new constructions built to the highest pharmaceutical industry standards for peptide manufacturing.
The US expansion includes the construction of a new large-scale manufacturing facility at the Corden Pharma Colorado site, alongside additional manufacturing capacity within the existing facility. This move addresses the increasing demand for Glucagon-like Peptide 1 (GLP-1) agonist medications used in treating diabetes and obesity. The expansion is backed by multiple long-term contracts totaling around €3 billion.
In Europe, Corden Pharma plans to construct a new state-of-the-art greenfield facility, adding peptide manufacturing capacity from early clinical stages to late-stage commercial production. The new site will integrate with Corden Pharma’s existing facility network, enhancing their service offerings for peptide-based drug development.
Acquired by Astorg in 2022, Corden Pharma aims to reach €1 billion in sales for its Peptide Platform and €1.8 billion in total group revenue by 2028. The new facilities will be fully integrated into its network of cGMP manufacturing sites, providing comprehensive support for innovators’ supply chains from active pharmaceutical ingredients (APIs) to drug products.
Dr. Michael Quirmbach, President & CEO of Corden Pharma Group, stated, “These investments will profoundly strengthen our ability to provide valuable and much-needed support to innovators for the benefit of patients. We are honored by the trust our customers have placed in us and proud to contribute decades of peptide manufacturing experience towards these transformative new medicines.”
The expansion reflects Corden Pharma’s commitment to becoming a leading CDMO for complex modalities such as peptides, offering fully-integrated services from APIs to drug products. Dr. Signe Michel, Managing Director at Astorg, expressed pride in Corden Pharma’s achievements and excitement about the future opportunities to enhance the company’s peptide offerings across the full drug lifecycle.
Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg, noted, “Corden Pharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large-scale manufacturing. Our latest commitment will help the company seize this opportunity.”
Overview of outsourcing trends 
